Frontage conducted a Proof-of-Concept study that evaluated a novel compound in subjects with Type 2 Diabetes (T2DM).
Register to gain access to gated resources.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
Frontage ran a Phase I Study of OMN54 (Aneustat™) in patients with advanced malignancies.
In this abstract, we discuss a Phase 1, open-label, two-period, sequential study to assess the effects of carvedilol phosphate on the pharmacokinetics of colchicine oral solution in healthy adult subjects.